Clinical Pharmacology: Advances and Applications (Sep 2022)
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
Abstract
Meredith B Oliver,1 Byron P Vaughn2 1M Health Fairview, Masonic Children’s Hospital, Minneapolis, MN, USA; 2Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USACorrespondence: Byron P Vaughn, Department of Medicine, 1-205 Philips Wangensteen Building, 516 Delaware Street S.E, MMC36, Minneapolis, MN, 55455, Tel +1 612 625 8999, Fax +1 612 625 5620, Email [email protected]: Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an appealing option for pediatric CDI to balance safety and efficacy. The purpose of this structured review was to outline the clinical evidence for safety and efficacy of fidaxomicin for pediatric CDI. A structured literature search was performed to identify relevant clinical data. Fidaxomicin is similarly effective to oral vancomycin with a lower rate of recurrent CDI. There were no serious safety signals reported with fidaxomicin. In conclusion, fidaxomicin is a safe and effective treatment option for pediatric CDI.Keywords: Dificid, diarrhea, colitis, microbiota
